UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/500/0.1/18.06.25 Stock UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/500/0.1/18.06.25
Add to a list
To use this feature you must be a member
Log inSign up

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/500/0.1/18.06.25 Stock

Warrant

DE000HC7U367

Real-time BOERSE MUENCHEN 11:40:15 2024-06-27 EDT
5.05 EUR +1.00% Intraday chart for UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/500/0.1/18.06.25
Current month+14.42%
1 month+12.61%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart VERTEX PHARMACEUTICALS INCORPORATED
Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/500/0.1/18.06.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540 MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes MT
More news

Quotes 5-day view

Date Price Change
24-06-27 5.05 +1.00%
24-06-26 5 +1.21%
24-06-25 4.94 -3.33%
24-06-24 5.11 +4.29%
24-06-21 4.9 -1.61%

Real-time BOERSE MUENCHEN

Last update June 27, 2024 at 11:40 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying VERTEX PHARMACEUTICALS INCORPORATED
IssuerLogo Issuer UniCredit UniCredit
WKN HC7U36
ISINDE000HC7U367
Date issued 2023-06-30
Strike 500 $
Maturity 2025-06-18 (356 Days)
Parity 10 : 1
Emission price 3.12 €
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 5.73 €
Lowest since issue 1.75 €
Delta0.56x
Omega 4.911
Premium16.66x
Gearing8.77x
Moneyness 0.9501
Difference Strike 24.9 $
Difference Strike %+4.98%
Spread 0.04 €
Spread %0.79%
Theoretical value 5.040
Implied Volatility 28.73 %
Total Loss Probability 55.36 %
Intrinsic value 0.000000
Present value 5.040
Break even 553.97 €
Theta-0.07x
Vega0.17x
Rho0.19x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
474 USD
Average target price
468.3 USD
Spread / Average Target
-1.21%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant